Ultragenyx Pharmaceutical (RARE) Exchange Rate Effect (2017 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Exchange Rate Effect of -$1.0 million for Q1 2026, down 200.0% year-over-year from $1.0 million in Q1 2025, and down 52.44% quarter-over-quarter from -$656000.0 in Q4 2025.
Powered by 
Analysis
Ultragenyx Pharmaceutical (RARE) Exchange Rate Effect (2017 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Exchange Rate Effect for 10 consecutive years, with -$1.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Exchange Rate Effect fell 200.0% year-over-year to -$1.0 million; the TTM figure through Mar 2026 stood at $2.0 million (up 723.05% YoY), while the FY2025 annual figure was $4.0 million, up 300.0% from the prior year.
- Exchange Rate Effect eased to -$1.0 million in Q1 2026 per RARE's latest filing, from -$656000.0 in the prior quarter.
- Across five years, Exchange Rate Effect topped out at $3.4 million in Q2 2025 and bottomed at -$1.9 million in Q4 2024.
- Historically, Exchange Rate Effect has averaged -$4411.8 across 5 years, with a median of -$136000.0 in 2023.
- Annual changes were most pronounced in 2024 — Exchange Rate Effect tumbled 421.8% — and 2025, when it soared 618.83%.
- Ultragenyx Pharmaceutical's Exchange Rate Effect stood at $1.4 million in 2022, then plunged by 52.59% to $641000.0 in 2023, then plunged by 403.9% to -$1.9 million in 2024, then surged by 66.32% to -$656000.0 in 2025, then sank by 52.44% to -$1.0 million in 2026.
- Business Quant data shows RARE's Exchange Rate Effect at -$1.0 million in Q1 2026, -$656000.0 in Q4 2025, and $294000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -2.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.84 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -287,000.00 |
| 10 | Ultragenyx Pharmaceutical | 1.56 Bn | 1.27 Bn | 180.00 Mn | 1.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.00 Mn |
| Mar 31, 2026 | -1.00 Mn |
| Dec 31, 2025 | -656,000.00 |
| Sep 30, 2025 | -344,000.00 |
| Jun 30, 2025 | 4.00 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | -1.95 Mn |
| Sep 30, 2024 | 1.28 Mn |
| Jun 30, 2024 | -648,000.00 |
| Mar 31, 2024 | -679,000.00 |
| Dec 31, 2023 | 641,000.00 |
| Sep 30, 2023 | -716,000.00 |
| Jun 30, 2023 | -136,000.00 |
| Mar 31, 2023 | 211,000.00 |
| Dec 31, 2022 | 1.35 Mn |
| Sep 30, 2022 | -1.08 Mn |
| Jun 30, 2022 | -1.24 Mn |
| Mar 31, 2022 | -108,000.00 |
| Dec 31, 2021 | -392,000.00 |
| Sep 30, 2021 | -479,000.00 |